Speakers

Dr. Gros has served as Chief Executive Officer and a member of the Board of Directors of Eledon Pharmaceuticals, Inc. since September 2020. He joined Eledon Pharmaceuticals from Imbria Pharmaceuticals Inc., where he served as Co-Founder, Chief Executive Officer and Chairman of the Board of Directors. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and of Saint Jean Groupe, S.A., a leading French manufacturer of pasta products since 1935. Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.

Dr. Perrin currently serves as our President and Chief Scientific Officer, a position he has held since September 2020. From January 2013 until joining Eledon in September 2020, Dr. Perrin was the founder and Chief Executive Officer of Anelixis Therapeutics Inc. Dr. Perrin has been Executive Chairman of the ALS Therapy Development Institute since June 2010. Dr. Perrin also served as Chief Scientific Officer for the ALS Therapy Development Institute from January 2007 to August 2018. He has 20 years of drug development experience, having held R&D positions at the Hoechst-Ariad Genomics Center, Aventis Pharmaceuticals, Inc., and Biogen Idec, Inc. Over the past decade, Dr. Perrin has worked with the ALS Therapy Development Institute to develop the world’s largest ALS drug development program, bridging preclinical and clinical programs. Dr. Perrin earned a Ph.D. in Biochemistry from Boston University Medical Center, where he also started his career as Associate Professor of Medicine, and a Bachelor of Science from Boston College.

Dr. Bornstein has served as the Chief Medical Officer of Eledon Pharmaceuticals since April 2021. Prior to joining Eledon, he served as Vice President, Head of Clinical Sciences, Gastroenterology at Takeda Pharmaceuticals, and he has previously led development programs at Biogen, Gilead Sciences, Elan Pharmaceuticals, and several early stage biotechs. Dr. Bornstein earned his Doctor of Medicine and completed his residency in internal medicine at McGill University. He also completed a fellowship in gastroenterology at Duke University Medical Center where he subsequently served on the faculty as an Assistant Professor of Medicine.

Dr. Flavio Vincenti is a Professor of Clinical Medicine in the Department of Medicine and the Kidney Transplant Service at the University of California San Francisco. Dr. Vincenti has participated in over 10,000 kidney transplants over 44 years at UCSF. He has extensive experience in clinical trials in particular those involving novel drug treatments for transplant recipients, and he has served as the Principal Investigator of several clinical trials of agents that ultimately received FDA approval, notably daclizumab and belatacept. With a bench-to-bedside approach, Dr. Vincenti’s main interest is in translational science focusing on early immunologic targets in kidney transplantation. He has also been a co-investigator of several biomarkers for rejection including KSORT and blood and urine donor derived cell free DNA. Dr. Vincenti has a strong background in the induction of tolerance in kidney transplant and has served as a scientific advisor to Eledon’s kidney transplant program.

Stanley H. Appel is the Co-Director of the Houston Methodist Neurological Institute, and Chair of the Stanley H. Appel Department of Neurology at Houston Methodist Hospital. He is the Peggy and Gary Edwards Distinguished Endowed Chair for the Treatment and Research of ALS, and Director of the Johnson Center for Cellular Therapeutics at Houston Methodist Research Institute, and Professor of Neurology at Weill Cornell Medical College. He was previously Chief of Neurology at Duke University Medical Center and subsequently at Baylor College of Medicine. He was Chair of the Research Advisory Committee of the Muscular Dystrophy Association, and a member of the Board of Directors of ALS Therapy Development Institute. He is Director of the MDA/ALSA ALS Research and Clinical Center at Houston Methodist Neurological Institute, and past Director of the National Institute of Aging Alzheimer’s Disease Research Center. He is Director of the Johnson Center for Cellular Therapeutics at Houston Methodist Hospital. Dr. Appel’s research has focused on developing new insights into neurodegenerative diseases with primary emphasis on ALS. Dr. Appel is an investigator in Eledon’s ALS Phase 2 trial.

Dr. Piotr P. Witkowski is an Associate Professor of Surgery at the Transplantation Institute at the University of Chicago. For the past 13 years he has served as the Director of the Pancreatic Islet Transplant Program, while also taking on the role of Director of the Transplant Fellowship Program for the past 4 years. In addition, he has served as a member of the UNOS, Pancreas and Islet Transplantation Committee for the past 2 years. He trained in transplant surgery at Columbia Presbyterian in New York City, and accomplished research fellowship in transplant immunology at the same institution. Dr. Witkowski is the Principal Investigator for Eledon’s US Islet Cell Transplant clinical trial.

Dr. Jonathan Barratt leads the Renal Research Group within the College of Life Sciences, University of Leicester. His research is focused on a bench to bedside approach to improving our understanding of the pathogenesis of IgA nephropathy. He is the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases and a member of the steering committee for the International IgA Nephropathy Network. He is a top advisor to many sponsors working on developing new treatments for IgA nephropathy and serves as the Principal Investigator for a number of international late-stage clinical trials in this area. He was a member of the FDA and American Society of Nephrology Kidney Health Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgA Nephropathy Work group. He is an Editorial Board member for Kidney International and Clinical Journal of the American Society of Nephrology and sits on the Kidney Research UK Grants Committee. He is also a co-Chair of the UK Glomerulonephritis Clinical Study Group and was IgA nephropathy lead for the recent revision of the KDIGO Clinical Practice Guidelines for Glomerular Diseases. Dr. Barratt is the Principal Investigator for Eledon’s Phase 2 IgAN trial.